Takeda gets European panel nod for Alunbrig to treat lung cancer
The European Medicines Agency's Committee for Medicinal Products for Human Use recommended granting Japan-based Takeda's Alunbrig, or brigatinib, a marketing authorisation.
New Delhi; Takeda Pharmaceutical Co's lung cancer drug received the recommendation of a European Union panel on Friday, more than a year after it won regulatory approval to be sold in the United States.
The European Medicines Agency's Committee for Medicinal Products for Human Use recommended granting Japan-based Takeda's Alunbrig, or brigatinib, a marketing authorisation.
The panel's recommendations are generally followed by European regulators.
Alunbrig was approved last year by the U.S. Food and Drug Administration as a second-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer, who have progressed on or are intolerant to Pfizer drug crizotinib, the standard initial treatment for the disease.
(Reporting by Sangameswaran S in Bengaluru; Editing by Sai Sachin Ravikumar)
Alunbrigcell lung cancercrizotinibEUEuropean UnionPfizer drugTakeda PharmaTakeda PharmaceuticalU.S. Food and Drug Administration
Source : ReutersMedical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Next Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd